Session date: 
10/05/2017 - 7:00am to 8:00am

Title:

COMPASS: A Large Simple Trial of 2.5 mg BID Rivaroxaban and 100mg/d Aspirin versus 100mg/d of Aspirin shows benefit for CAD, PAD and Complex CVD Outcome

Speaker:

Dr. Jeffrey Probstfield

Learning Objectives:

1. Compare 2.5mg BID Rivaroxaban and 100mg/d Aspirin showing the benefit for complex cardiovascular outcome, PAD and CAD vs. 100mg/d Aspirin.

2. Review 5mg BID Rivaroxaban vs. 100mg/d Aspirin showing no benefit on same outcomes.

3. Assess small increas incidence of bleeding (NS).

4. Estimate same incidence of cerebral vascular bleeding in both treatment groups.

Location:

MCH Waugh Side A; MCB 116E

Where did the idea for the course originate?: 
Arizona
Please login or register to take this course.
Where did the idea for the course originate?: 
Arizona